Research
Hormonal
GLP-1 receptor agonists reduce systolic blood pressure by 1.7 to 10.6 mmHg compared to placebo, contributing to stroke risk reduction.
GLP-1 drugs can help lower blood pressure, which is a key factor in preventing stroke. This effect is seen across different drugs in this class, with some showing reductions of up to 10 mmHg.
GoodSupportsHIGH confidence
These findings correlate with the results obtained in the REWIND study, where the use of dulaglutide was associated with a reduction of the systolic blood pressure of 1.7 mmHg when compared to placebo [16]. Also, in the SCALE study, liraglutide reduced the systolic blood pressure by 2.8 mmHg compared to placebo and, in the STEP-1 trial, semaglutide reduced the blood pressure by 5.1 mmHg systolic and 2.4 mmHg diastolic compared to placebo. Furthermore, the use of once weekly subcutaneous tirzepatide, a dual GLP1RAs and GIP agonist, reduced the systolic blood pressure from baseline by 7.4 to 10.6 mmHg, compared to placebo [28].
Why this rating
Based on multiple randomized clinical trials showing consistent, albeit modest, reductions in blood pressure.
Source
Emerging Treatments for Obesity: the Role of GLP1 Receptor Agonists on Stroke
Melissa Mariscal et al. · Current Neurology and Neuroscience Reports · 2025
DOI 10.1007/s11910-025-01423-9
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP1RAs) reduce the risk of total stroke by approximately 16-17% and non-fatal stroke by 15-16% in patients with type 2 diabetes, independent of their effects on weight loss.Strong
- GLP-1 receptor agonists reduce the risk of atrial fibrillation by approximately 42% compared to placebo, which is a significant risk factor for stroke.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →